GenSight Biologics raises nearly €4 million in private placement

On July 1, 2025, GenSight Biologics announced the successful completion of a €3.9 million private placement. This financial injection, supported by existing and new investors, will primarily contribute to the development of LUMEVOQ®, an advanced Phase III treatment. GenSight expects to use approximately 77% of the funds to continue its development, including the anticipated compassionate access trial in France.

Laurence Rodriguez, CEO, highlights GenSight's unique market positioning. The funds will also help manage financial obligations, extending the company's cash flow horizon until early October 2025.

Jan Eryk Umiastowski, Chief Financial Officer, reaffirms this investor confidence, paving the way for the activation of the ACC program in the fourth quarter. The resulting shares will be traded on Euronext Paris starting July 3, 2025, thus consolidating the company's stock market position.